- Companies
- AMBOSS
AMBOSS Funding, Investors & Competitors
AMBOSS has raised $298M across 3 funding rounds, most recently a $260M undisclosed-stage round in March 2025.
Last AMBOSS funding round
$260M
Undisclosed stage · Mar 2025
Cumulative funding AMBOSS raised
$298M
across 3 funding rounds
Key investors in AMBOSS
Cherry Ventures
Partech
Target Global
Lightrock
Wellington Partners
Burda Principal Investments
M&G Investments
KIRKBI
About AMBOSS
AMBOSS is a Berlin-based medical technology company, founded in 2012 by physicians, that provides a knowledge and clinical decision-support platform for doctors, medical students, and other healthcare professionals. The platform combines expert medical content with AI-driven delivery to support education, exam preparation, diagnostics, and treatment recommendations based on current clinical guidelines. It serves more than a million users across over 180 countries and has expanded beyond physicians into nursing education through acquisitions including Novaheal and NEJM Knowledge+.
Founded
2012
HQ
Website
Status
Privately held
Customer focus
B2B & B2C
Revenue model
Subscription
AMBOSS Funding History
AMBOSS has raised a total of $298M across 3 funding rounds.
AMBOSS's first fundraising round was a $5M Series A in January 2017. The most recent completed round was a $260M undisclosed-stage round in March 2025.
AMBOSS funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Mar 2025 | Undisclosed stage | KIRKBI; M&G Investments; Burda Principal Investments; Lightrock | $260M | AMBOSS, a Berlin-based medical technology company founded in 2012, provides an all-in-one knowledge platform serving as a digital co-pilot for physicians, medical students, and healthcare professionals worldwide. The platform combines expert medical content with AI-driven delivery for education, clinical decision-making, diagnostics, and treatment recommendations based on latest guidelines, with over half a million users in 180+ countries. It recently expanded beyond physicians to nurses and other segments via acquisitions like Novaheal in 2024 and NEJM Knowledge+. The company employs over 500 people from 50+ countries, including 150+ physicians, engineers, and scientists, emphasizing in-house collaboration for rigorous, validated content. On March 25, 2025, AMBOSS closed a €240M (approximately $258.81M or $259.6M) financing round, described variably as Series C or growth equity, led by new long-term investors KIRKBI, M&G Investments, and Lightrock, with participation from Burda Principal Investments and others. This followed total prior funding bringing cumulative raised to around $291M-$297M. Funds will support international market expansion, technology investments including AI enhancements, platform capabilities for new healthcare segments like nursing, and selective acquisitions, while converting to a European stock corporation (SE) for flexibility toward a potential future IPO. AMBOSS positions itself in the growing HealthTech sector, focusing on responsible AI to empower professionals without replacing expertise. |
| Jul 2019 | Series B | Partech (lead); Target Global (lead); Wellington Partners; Holtzbrinck Digital; Cherry Ventures | $33M | AMBOSS is a medical knowledge platform and clinical decision support system founded in 2012 by physicians in Berlin, Germany. The company provides learning and clinical reference tools for medical students, residents, and healthcare professionals, with particular strength in US medical licensing exam preparation and daily clinical decision-making support. In September 2019, AMBOSS closed a €30 million Series B funding round led by Partech's growth fund and Target Global, with participation from existing investors Cherry Ventures, Wellington Partners, and Holtzbrinck Digital. The company had achieved over 90% market share in its core medical education segment within less than two years of launch and was accelerating global expansion. By 2024, AMBOSS had grown to over 500 employees across more than 50 countries, including 150+ physicians on staff, and serves over 1 million professional users across 180 countries. In March 2025, the company raised €240 million at a €2 billion valuation, representing significant growth since the 2019 Series B. AMBOSS has pursued a selective acquisition strategy, acquiring Novaheal (nursing education platform) and NEJM Knowledge+ (board exam prep for US residents) in 2024. |
| Jan 2017 | Series A | Cherry Ventures (lead) | $5M | AMBOSS raised $5.6 million (equivalent to €5 million) in its Series A funding round in 2017 from Cherry Ventures. The round occurred around December 30, 2017. This was the company's first institutional funding ahead of later rounds including a €30 million Series B in 2019 and a €240 million financing in 2025. |
Who has invested in AMBOSS?
9 investors have backed AMBOSS across its funding rounds, including Cherry Ventures, Partech, Target Global, Lightrock, Wellington Partners and Burda Principal Investments.
Lead investors include Partech, Target Global and Cherry Ventures.
AMBOSS Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Lead | Jan 2017 | ||
| 1 | Participant | Mar 2025 | ||
| 1 | Lead | Jul 2019 | ||
| 1 | Participant | Mar 2025 | ||
| 1 | Participant | Mar 2025 | ||
| 1 | Participant | Jul 2019 | ||
| 1 | Lead | Jul 2019 | ||
This data is available for Pro users. Sign up to see all 9 AMBOSS investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by AMBOSS
AMBOSS has acquired 2 companies to date.
Last acquisition by AMBOSS was on October 3rd 2024. AMBOSS acquired Novaheal for undisclosed valuation.
Latest Acquisitions by AMBOSS
| Description | Novaheal is a Berlin-based online learning platform for nursing trainees and early-career professionals. It offers modules on patient care, pharmacology, and emergency response compliant with German nursing standards. Users access interactive simulations, video case studies, and certification prep across desktop and mobile devices. | NEJM Knowledge+ is a digital adaptive learning platform developed by NEJM Group, part of the Massachusetts Medical Society. It delivers board review and continuing medical education content for internal medicine and 14 subspecialties, including cardiology, gastroenterology, and hematology. The platform uses spaced repetition and question banks exceeding 2,200 items to prepare clinicians for ABIM certification exams and Maintenance of Certification requirements. Boston-headquartered NEJM Group launched the service in 2014, serving thousands of physicians worldwide through web and mobile access. |
| HQ Country | ||
| HQ City | Bochum | Boston, MA |
| Deal Date | 3 Oct 2024 | 25 Apr 2024 |
| Valuation | undisclosed | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all AMBOSS acquisitions and their M&A valuation multiples. Start Free Trial | ||
AMBOSS Competitors
AMBOSS competitors include listed companies like IDEXX Laboratories, GE HealthCare, United Imaging and Glaukos, and private ones like Dental Monitoring and AcuityMD.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $4.3B | $1.5B | $40B | 8.9x | ||
| Publicly listed | $21B | $3.7B | $29B | 1.8x | ||
| Publicly listed | $2.1B | $367M | $12B | 4.8x | ||
| Publicly listed | $507M | ($157M) | $9.5B | 14.6x | ||
| Private | $91M | - | $1B | - | ||
| Private | - | - | $955M | - |
AMBOSS Public Comps
AMBOSS is still privately-owned, but its public comps include Samsung, Johnson & Johnson, Roche, Thermo Fisher Scientific, Siemens, Abbott, Danaher, Intuitive Surgical, Medtronic and Stryker.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $243B | $67B | 4.4x | 2.4x | 15.8x | 4.4x | |||
| $94B | $40B | 7.2x | 6.8x | 17.0x | 18.3x | |||
| $77B | $26B | 5.0x | 4.9x | 14.6x | 12.4x | |||
| $45B | $11B | 6.3x | 6.0x | 26.8x | 23.6x | |||
| $91B | $15B | 3.0x | 2.9x | 18.1x | 15.7x | |||
| $44B | $12B | 4.6x | 4.2x | 17.4x | 15.8x | |||
| $25B | $6.9B | 7.0x | 6.6x | 24.8x | 21.1x | |||
| $10B | $3.6B | 13.0x | 11.6x | 36.6x | 25.7x | |||
This data is available for Pro users. Sign up to see all AMBOSS competitors and their valuation data. Start Free Trial | ||||||||
Common questions about AMBOSS
| When was AMBOSS founded? | AMBOSS was founded in 2012. |
| Where is AMBOSS headquartered? | AMBOSS is headquartered in Germany. |
| Is AMBOSS publicly listed? | No, AMBOSS is a private, VC-backed company. |
| How much funding has AMBOSS raised? | AMBOSS has raised $298M across 3 funding rounds. |
| What was AMBOSS's last funding round? | AMBOSS's last funding round was a $260M undisclosed-stage round in March 2025. |
| Who are AMBOSS's investors? | AMBOSS's investors include Cherry Ventures, KIRKBI, Partech, M&G Investments, Burda Principal Investments, Wellington Partners, Target Global, Holtzbrinck Digital and Lightrock. |
| Which companies are comparable to AMBOSS? | Companies comparable to AMBOSS include IDEXX Laboratories, GE HealthCare, United Imaging, Glaukos, Dental Monitoring and AcuityMD. |
| How many companies has AMBOSS acquired? | AMBOSS has acquired 2 companies, including Novaheal and NEJM Knowledge+. |
See companies similar to AMBOSS
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




